Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EPRX NASDAQ:FDMT NASDAQ:GNFT NASDAQ:RENB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPRXEupraxia Pharmaceuticals$5.30-1.8%$4.79$2.20▼$6.20$194.18M1.5111,620 shs4,758 shsFDMT4D Molecular Therapeutics$6.42+42.7%$4.21$2.23▼$17.41$208.46M2.83360,319 shs31.47 million shsGNFTGENFIT$3.82-2.9%$3.98$2.55▼$6.42$196.76M1.142,827 shs2,836 shsRENBRenovaro$0.26+1.2%$0.32$0.25▼$2.10$43.98M0.541.35 million shs571,136 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPRXEupraxia Pharmaceuticals-1.78%-3.39%-3.03%+32.43%+86.76%FDMT4D Molecular Therapeutics+42.67%+40.48%+48.96%+70.74%-63.79%GNFTGENFIT-0.52%-1.55%+0.26%-10.86%-9.38%RENBRenovaro+1.17%-16.32%-7.45%-23.04%-64.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEPRXEupraxia Pharmaceuticals2.5434 of 5 stars3.62.00.00.02.60.00.6FDMT4D Molecular Therapeutics2.513 of 5 stars3.33.00.00.02.51.70.6GNFTGENFIT1.6953 of 5 stars3.53.00.00.01.90.00.0RENBRenovaro0.9234 of 5 stars0.03.00.00.00.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEPRXEupraxia Pharmaceuticals 3.17Buy$11.00107.39% UpsideFDMT4D Molecular Therapeutics 2.60Moderate Buy$29.56360.37% UpsideGNFTGENFIT 3.00Buy$13.00240.76% UpsideRENBRenovaro 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RENB, GNFT, FDMT, and EPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/1/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.007/29/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)7/24/2025EPRXEupraxia PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$11.007/12/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)7/3/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.006/27/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (E+)6/26/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/26/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/16/2025EPRXEupraxia PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSpeculative Buy6/11/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)5/24/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AN/AFDMT4D Molecular Therapeutics$40K7,435.97N/AN/A$11.05 per share0.58GNFTGENFIT$76.77M2.48$0.07 per share56.26$1.50 per share2.54RENBRenovaroN/AN/AN/AN/A$0.89 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEPRXEupraxia Pharmaceuticals-$25.50M-$0.76N/AN/AN/AN/A-367.73%-112.23%8/6/2025 (Estimated)FDMT4D Molecular Therapeutics-$160.87M-$3.18N/AN/AN/A-767,126.06%-33.26%-30.68%8/6/2025 (Estimated)GNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/AN/ARENBRenovaro-$88.43M-$0.77N/A∞N/AN/A-60.38%-47.04%9/29/2025 (Estimated)Latest RENB, GNFT, FDMT, and EPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FDMT4D Molecular Therapeutics-$0.6922N/AN/AN/A$0.52 millionN/A8/6/2025N/AEPRXEupraxia Pharmaceuticals-$0.21N/AN/AN/AN/AN/A5/8/2025Q1 2025FDMT4D Molecular Therapeutics-$0.84-$0.86-$0.02-$0.86$0.53 millionN/A5/6/2025Q1 2025EPRXEupraxia Pharmaceuticals-$0.19-$0.21-$0.02-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/ARENBRenovaroN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEPRXEupraxia PharmaceuticalsN/A11.1011.10FDMT4D Molecular TherapeuticsN/A12.3612.36GNFTGENFIT0.081.231.23RENBRenovaroN/A0.130.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEPRXEupraxia PharmaceuticalsN/AFDMT4D Molecular Therapeutics99.27%GNFTGENFIT2.24%RENBRenovaro71.41%Insider OwnershipCompanyInsider OwnershipEPRXEupraxia PharmaceuticalsN/AFDMT4D Molecular Therapeutics9.60%GNFTGENFIT4.20%RENBRenovaro21.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEPRXEupraxia Pharmaceuticals2935.96 millionN/AN/AFDMT4D Molecular Therapeutics12046.33 million41.88 millionOptionableGNFTGENFIT12050.00 million47.90 millionNot OptionableRENBRenovaro20172.12 million134.74 millionOptionableRENB, GNFT, FDMT, and EPRX HeadlinesRecent News About These CompaniesAI Just Got a Green Light from the White House--Here's What That Means for Healthcare StocksJuly 30 at 8:24 AM | tmcnet.comRenovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI SectorJuly 28, 2025 | accessnewswire.comARenovaro (NASDAQ:RENB) Trading 0.1% Higher - Here's What HappenedJuly 23, 2025 | americanbankingnews.comRenovaro (NASDAQ:RENB) Trading 0.1% Higher - Time to Buy?July 23, 2025 | marketbeat.comRenovaro Biosciences: Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor EfficacyJuly 17, 2025 | finanznachrichten.dePeer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor EfficacyJuly 17, 2025 | accessnewswire.comARenovaro Biosciences Receives Nasdaq Compliance NoticeJuly 14, 2025 | tipranks.comRenovaro Strengthens Balance Sheet Through Debt ... - MorningstarJuly 11, 2025 | morningstar.comMRenovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven InitiativesJuly 9, 2025 | accessnewswire.comARenovaro Biosciences Restructures Debt with Exchange AgreementJuly 9, 2025 | tipranks.comRenovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs - NasdaqJuly 2, 2025 | nasdaq.comRenovaro Biosciences: Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs - FinanzNachrichten.deJuly 2, 2025 | finanznachrichten.deRenovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security NeedsJune 30, 2025 | accessnewswire.comARenovaro subsidiary secures patent for drug discovery AIJune 5, 2025 | uk.investing.comRENB-aandeel raakt 52-weeks dieptepunt van $ 0,27 door marktuitdagingenJune 5, 2025 | nl.investing.comRenovaro Obtains a U.S. Patent for its AI-Powered Platform for Medication Discovery and DiagnosticsJune 5, 2025 | msn.comRENB stock touches 52-week low at $0.27 amid market challengesJune 5, 2025 | investing.comRenovaro-dochter verkrijgt patent voor AI-gestuurde medicijnontwikkelingJune 3, 2025 | nl.investing.comRenovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics PlatformJune 3, 2025 | globenewswire.comRenovaro Inc. Secures Ruling to Expedite Trial Against Predictive Oncology Over Breach of Merger AgreementMay 24, 2025 | nasdaq.comRenovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology MergerMay 22, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRENB, GNFT, FDMT, and EPRX Company DescriptionsEupraxia Pharmaceuticals NASDAQ:EPRX$5.30 -0.10 (-1.78%) Closing price 08/1/2025 03:50 PM EasternExtended Trading$5.58 +0.27 (+5.18%) As of 08/1/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.4D Molecular Therapeutics NASDAQ:FDMT$6.42 +1.92 (+42.67%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.38 -0.04 (-0.64%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.GENFIT NASDAQ:GNFT$3.82 -0.12 (-2.93%) As of 08/1/2025 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Renovaro NASDAQ:RENB$0.26 +0.00 (+1.17%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.26 0.00 (-1.35%) As of 08/1/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
